The company initiates the P-I study to evaluate the safety, tolerability, dose-limited toxicity & PK profile of JWATM204 in patients with HCC. The trial also evaluates the anti-tumor activity in the target population
The 5yr. survival rate was 15%-19% in North America, ORRs of 17%-20% & 15%-20% for the 1 & 2L therapies in HCC patients. The preclinical studies showed continued clinical development potential of JWATM204 for HCC
JWATM204 is a GPC-3 mAb created at the ARTEMIS® T-cell platform with high affinity & specificity. The company obtained an in-license from Eureka to develop, manufacture & commercialize JWATM204 in China (incl. mainland China, Hong Kong, Macao & Taiwan) and the member countries of the association of Southeast Asian nations in 2020
Ref: PRNewswire | Image: JW Therapeutics
